These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 19331127

  • 1. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
    Guan M, Zhu L, Somlo G, Hughes A, Zhou B, Yen Y.
    Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
    [Abstract] [Full Text] [Related]

  • 2. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
    Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H, Yen Y.
    Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
    [Abstract] [Full Text] [Related]

  • 3. Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.
    Otsuka M, Mizuki M, Fujita J, Kang S, Kanakura Y.
    Anticancer Res; 2011 Jan; 31(1):113-22. PubMed ID: 21273588
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.
    Clin Cancer Res; 2007 Nov 01; 13(21):6469-78. PubMed ID: 17975159
    [Abstract] [Full Text] [Related]

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 7. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.
    Clin Cancer Res; 2009 Jan 15; 15(2):520-31. PubMed ID: 19147757
    [Abstract] [Full Text] [Related]

  • 8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W, Chen J, Chuang M, Jiang D.
    APMIS; 2012 Mar 15; 120(3):195-203. PubMed ID: 22339676
    [Abstract] [Full Text] [Related]

  • 9. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
    Kim HJ, Kim SM, Park KR, Jang HJ, Na YS, Ahn KS, Kim SH, Ahn KS.
    Cancer Lett; 2011 Feb 01; 301(1):29-37. PubMed ID: 21122982
    [Abstract] [Full Text] [Related]

  • 10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 11. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
    Kim SH, Ahn KS, Jeong SJ, Kwon TR, Jung JH, Yun SM, Han I, Lee SG, Kim DK, Kang M, Chen CY, Lee JW, Kim SH.
    Eur J Pharmacol; 2011 Mar 01; 654(1):10-6. PubMed ID: 21172343
    [Abstract] [Full Text] [Related]

  • 12. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
    Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, Embry MG, Swinarski DE, Garrett EN, Pryer NK, Trudel S, Jallal B, Mendel DB, Heise CC.
    Clin Cancer Res; 2006 Aug 15; 12(16):4908-15. PubMed ID: 16914579
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K.
    Oncogene; 2009 Jan 15; 28(2):231-42. PubMed ID: 18850009
    [Abstract] [Full Text] [Related]

  • 14. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 15. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.
    Eur J Haematol; 2010 Mar 01; 84(3):201-11. PubMed ID: 19929977
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY, Yoon SS.
    Anticancer Drugs; 2008 Sep 01; 19(8):777-82. PubMed ID: 18690088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.